Wang Zi, Jiang Yuanyuan, Chen Pei, Wang Jinwei, Zhang Xue, Huang Bo, Zhou Xujie, Shi Sufang, Liu Lijun, Lv Jicheng, Zhang Hong
Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
Nephrol Dial Transplant. 2022 Oct 19;37(11):2119-2127. doi: 10.1093/ndt/gfac024.
Positive glomerular C4d staining, representative of lectin pathway activation, has been proven to be associated with unfavorable outcomes in immunoglobulin A nephropathy (IgAN). Our previous study suggested that urinary C4d correlated positively with an increase in crescents while the relationship between urinary C4d and disease severity and progression remains unelucidated.
In this study we enrolled 168 patients diagnosed with IgAN with varying proportions of crescent formation at the time of biopsy. An independent cohort of 107 IgAN patients was enrolled for validation. Kidney biopsy specimens were stained using immunohistochemistry. Urinary C4d levels at renal biopsy were measured by enzyme-linked immunosorbent assay. The primary endpoint was end-stage kidney disease (ESKD).
Higher urinary C4d/creatinine levels were associated with a lower estimated glomerular filtration rate (eGFR); massive proteinuria; hypertension and severe Oxford M, E, T and C scores. After a median follow-up of 19 months (interquartile range 9-27), 53 (31.5%) participants reached ESKD. High urinary C4d/creatinine levels were independently and significantly associated with a risk of developing ESKD [hazard ratio per standard deviation increment of log-transformed C4d/creatinine 7.623 (95% confidence interval 4.117-14.113)].
The urinary C4d/creatinine level is a potential useful biomarker that was associated with disease severity and progression in patients with IgAN and crescents.
肾小球C4d染色阳性代表凝集素途径激活,已被证明与免疫球蛋白A肾病(IgAN)的不良预后相关。我们之前的研究表明,尿C4d与新月体增加呈正相关,但尿C4d与疾病严重程度和进展之间的关系仍不明确。
在本研究中,我们纳入了168例经活检确诊为IgAN且新月体形成比例各异的患者。另外纳入107例IgAN患者的独立队列进行验证。肾活检标本采用免疫组织化学染色。通过酶联免疫吸附测定法测量肾活检时的尿C4d水平。主要终点是终末期肾病(ESKD)。
较高的尿C4d/肌酐水平与较低的估计肾小球滤过率(eGFR)、大量蛋白尿、高血压以及严重的牛津M、E、T和C评分相关。中位随访19个月(四分位间距9 - 27个月)后,53例(31.5%)参与者达到ESKD。高尿C4d/肌酐水平与发生ESKD的风险独立且显著相关[对数转换后的C4d/肌酐每增加一个标准差的风险比为7.623(95%置信区间4.117 - 14.113)]。
尿C4d/肌酐水平是一种潜在有用的生物标志物,与IgAN和新月体患者的疾病严重程度及进展相关。